Genotoxicity studies on a high-purity rebaudioside A preparation
Lonnie D Williams1, George A Burdock
1Burdock Group, 801 N. Orange Ave, Suite 710, Orlando, FL 32801, USA. lwilliams@burdockgroup.com
Summary
Rebaudioside A (Reb A), a natural sweetener from Stevia, was evaluated for genotoxicity. Studies confirmed Reb A is not mutagenic or genotoxic, supporting its safe use in food products.
Area of Science:
- Food Science
- Toxicology
- Biochemistry
Background:
- Rebaudioside A (Reb A) is a natural, non-nutritive sweetener derived from Stevia rebaudiana.
- It is significantly sweeter than sucrose and has growing applications in the food industry.
- Concerns regarding the safety of food additives necessitate thorough toxicological evaluation.
Purpose of the Study:
- To assess the genotoxic potential of Rebaudioside A.
- To provide comprehensive safety data for Rebaudioside A.
- To support the Generally Recognized As Safe (GRAS) status of Reb A.
Main Methods:
- Conducted three in vitro genotoxicity assays: Ames test, chromosomal aberration test, and mouse lymphoma assay.
- Performed two in vivo genotoxicity assays: bone marrow micronucleus test and unscheduled DNA synthesis test.
- All studies adhered to OECD guidelines and included metabolic activation where applicable.
Main Results:
- Rebaudioside A demonstrated no mutagenicity in bacterial assays (Ames test).
- Reb A did not induce chromosomal aberrations in mammalian cells or gene mutations in the mouse lymphoma assay.
- In vivo studies showed no evidence of genotoxicity in mice or rats at tested doses.
Conclusions:
- The conducted studies provide robust evidence that Rebaudioside A is not genotoxic.
- These findings support the established safety profile of Reb A for consumption.
- Reb A can be considered safe for widespread use in the diet.
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:23Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
01:16In vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.